Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Potential infant risks include: Altered feeding Slowed weight gain Gastrointestinal effects These outcomes have not been documented in humans
There are no disease modifying therapies for diabetes
Diabetes Care , 46 (Supplement 1), S1-S291
[3] [5] For patients with LDL-C 190 mg/dL, high-intensity statins are first-line therapy, with consideration of ezetimibe, bempedoic acid, or PCSK9 inhibitors for additional lowering
Ricciotti and FitzGerald 2011)
US$ 28.23
US$ 21.37
US$ 27.05
US$ 21.27
US$ 20.57
